Alembic Pharma receives USFDA approval for Zolmitriptan

Alembic Pharmaceuticals has received USFDA approval for Zolmitriptan Orally Disintegrating tablets, used for the treatment of migraine, in the American market. The product is therapeutically equivalent to the reference listed drug product (RLD) Zolmig-ZMT Orally Disintegrating tablets of AstraZeneca Pharmaceutical Company in the same strengths. The tablets are indicated for acute treatment of migraine in adults.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*